Femasys (NASDAQ:FEMY) Price Target Lowered to $10.00 at Chardan Capital

Femasys (NASDAQ:FEMY) had its target price decreased by Chardan Capital from $12.00 to $10.00 in a report issued on Wednesday morning, Benzinga reports. Chardan Capital currently has a buy rating on the stock.

Separately, HC Wainwright decreased their price target on shares of Femasys from $13.00 to $12.00 and set a buy rating on the stock in a report on Friday, August 9th.

Femasys Stock Performance

Shares of FEMY opened at $1.09 on Wednesday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 8.02 and a current ratio of 8.43. The stock has a market capitalization of $24.22 million, a price-to-earnings ratio of -1.30 and a beta of -2.81. Femasys has a 52-week low of $0.25 and a 52-week high of $4.75. The stock’s 50-day simple moving average is $1.09 and its 200 day simple moving average is $1.30.

Femasys (NASDAQ:FEMY) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). The firm had revenue of $0.22 million during the quarter, compared to analysts’ expectations of $0.50 million. Femasys had a negative return on equity of 104.06% and a negative net margin of 1,420.59%. Research analysts forecast that Femasys will post -0.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Femasys stock. Clear Creek Financial Management LLC raised its stake in Femasys Inc. (NASDAQ:FEMY) by 30.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 309,274 shares of the company’s stock after buying an additional 72,505 shares during the period. Clear Creek Financial Management LLC owned about 1.40% of Femasys worth $479,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.